You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. Read More These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 13
AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory clearances achieved that enable integration of the plato™ platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA; AVROBIO plans to open U.S. clinical trial sites for its ongoing multi-country FAB-201 trial Next interim Fabry clinical data update anticipated during summer 2019 Investigator-sponsored cystinosis clinical trial on track to start in the se...
Yahoo FinanceMay 12
Here’s What Hedge Funds Think About AVROBIO, Inc.
"Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back at all-time highs before we know it. I remain focused on preserving and growing our capital, and continue to believe that the best way to do so is via a value-driven, concentrate...
Yahoo FinanceApr 29
AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients AVROBIO to incorporate U.S. clinical sites into its ongoing global FAB-201 Phase 2 clinical trial in Fabry disease AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applicati...
-$0.72 per share
-$0.72 per share